Abstract: The invention relates to the cosmetic use, as a skin moisturizer, of a compound of formula (I): with (i) R1 and R2 represent a hydrogen atom or a C1-C6-alkyl group, or (ii) R1 and R2 can form, together with the nitrogen atom which bears them, a saturated heterocycle with 5 to 7 ring members; R5 representing a hydrogen atom or a (C1-C3) alkyl group; R6 representing a hydrogen atom or a (C1-C4) alkyl group; R3 represents a hydrogen atom or a (C1-C6) alkyl-group, or —OR3 represents a phosphate group; it being possible for the two groups R3 to form, together, an isopropylidene group; R4 represents a hydrogen atom or —OR4 represents a-phosphate group; and the salts, solvates and isomers thereof. The invention also relates to a cosmetic composition comprising a compound (I) and the corresponding new compounds.
Abstract: Disclosed are compounds of the formula: where variables Z, X, R15, R2, R3, and Rc are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.
Type:
Grant
Filed:
June 6, 2006
Date of Patent:
January 12, 2010
Assignee:
Elan Pharmaceuticals, Inc.
Inventors:
Varghese John, Michel Maillard, James P. Beck, Eric T. Baldwin, Robert Hughes, Shon R. Pulley, Ruth T. TenBrink
Abstract: A composition is disclosed which is characterized by a special combination of one or more disinfecting substances and one or more stabilizing substances. The composition is useful as a disinfectant. The composition may additionally include one or more insecticidal substances for use as an insecticide.
Abstract: Disclosed herein is a method of using colchicine. In one embodiment, the method comprises administering to a patient colchicine and a substrate of cytochrome P450 1A2 and monitoring the patient during administration of colchicine and the substrate for an adverse event. Also disclosed are articles of manufacture comprising a container containing a dosage form of colchicine and a method of manufacturing a colchicine product.
Type:
Application
Filed:
June 23, 2009
Publication date:
December 24, 2009
Applicant:
MUTUAL PHARMACEUTICAL COMPANY, INC.
Inventors:
Matthew W. Davis, Jie Du, Kurt R. Nielsen, Richard H. Roberts
Abstract: Disclosed are new colchicine solid-state forms, methods of preparing the solid-state forms, as well as formulations prepared therefrom and uses thereof.
Type:
Application
Filed:
April 14, 2009
Publication date:
December 17, 2009
Inventors:
Tong Sun, Kurt Nielsen, Shawn Watson, Rolf Hilfiker, Andreas Sieber
Abstract: A method of combating prostate cancer in a mammalian individual, the method comprising administering an inhibitor of glycogen synthase kinase-3 (GSK-3), or a polynucleotide which encodes an inhibitor of GSK-3, to the individual. A further anti-cancer agent can also be administered. Use of an inhibitor of GSK-3, or a polynucleotide which encodes an inhibitor of GSK-3, in the preparation of a medicament for combating prostate cancer. The medicament may contain a further anti-cancer agent.
Abstract: The present application describes deuterium-enriched arformoterol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: A contact lens kit may include one or more soft contact lenses stored in an ophthalmologically acceptable solution of hyaluronic acid or a salt of hyaluronic acid. A method of disinfecting a soft contact lens, storing a soft contact lens, or facilitating insertion of a soft contact lens in an eye, may include placing the soft contact lens into an ophthalmologically acceptable solution that comprises (a) hyaluronic acid or a salt of hyaluronic acid, and (b) at least one compound to disinfect, store, or facilitate insertion of the contact lens.
Abstract: The invention relates to compositions comprising at least one xanthine compound, preferably further comprising at least one agent which acts on capillary circulation and/or at least one natural moisturizing agent, which can be used to treat, or to reduce and/or minimize the appearance of, defects such as dark circles, bags and/or puffiness around eyes.
Type:
Application
Filed:
May 7, 2009
Publication date:
October 22, 2009
Applicant:
L'Oreal S.A.
Inventors:
Anthony Potin, Isabelle Bossant, Camille Amar
Abstract: Antimicrobial or preservative compositions with high user comfort and/or low ocular irritation. The compositions comprise a polyquaternary ammonium compound and an amidoamine having an alcohol group and exhibit synergistic antimicrobial activity. The compositions may be used as stand-alone antimicrobials/preservatives or may be incorporated into other ocular compositions such as those for ocular lens care or the treatment of ocular conditions.
Abstract: The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 ?-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.
Type:
Grant
Filed:
April 30, 2008
Date of Patent:
September 29, 2009
Assignees:
Resolvyx Pharmacuticals, Inc., The Brigham and Women's Hospital
Inventors:
Daniel W. Goodman, Michael R. Hanley, Stuart L. Bursten, Charles N. Serhan
Abstract: The invention relates to novel crystalline forms of 3-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)-phenoxy]-phenyl]-amino]-3-oxopropanoic acid, said crystalline forms being characterised by a powder X-ray diffraction pattern having major peaks at either 2?=16.1±0.2, 20.1±0.2, 20.7±0.2, and 24.2+0.2; or 2?=9.0±0.2, 14.7±0.2, 19.6±0.2, 21.6±0.2, and 24.3+0.2.
Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
Abstract: The present invention is generally directed to moisturizing and lubricating compositions for use on the bodyfacing surface of an absorbent product or on one or both faces of a tissue product. The moisturizing and lubricating compositions comprise an emollient, a humectant, and immobilizing agent and a compatibilizing agent. Optionally, the moisturizing and lubricating compositions can comprise a dispersing agent.
Type:
Application
Filed:
May 7, 2009
Publication date:
September 3, 2009
Applicant:
KIMBERLY-CLARK WORLDWIDE, INC.
Inventors:
Wael R. Joseph, Keisha Clarke, Duane G. Krzysik, Bernard J. Minerath, III
Abstract: The invention relates to compounds of the formula (I) in which A1, A2, R1, R2, R3, R4, R5 and X are as defined in the description, to processes and intermediates for their preparation, and to their use for controlling pests.
Type:
Application
Filed:
May 6, 2006
Publication date:
September 3, 2009
Inventors:
Iris Escher, Michael Müller, Peter Jeschke, Michael Beck, Oliver Gaertzen, Olga Malsam, Peter Lösel, Ulrich Ebbinghaus-Kintscher, Christian Arnold, Karl-Josef Haack
Abstract: The present invention relates to the use of sphingolipids for the preparation of a food item, a food supplement and/or a medicament for the treatment and/or prevention of insulin resistance, diabetes mellitus type 2 and/or Metabolic Syndrome. In particular, the invention relates to the use of a sphingolipid with the general formula (I): wherein Z is R3 or —CH(OH)—R3; A is sulphate, sulphonate, phosphate, phosphonate or —C(O)O—; R1 is H, hydroxyl, alditol, aldose, an alcohol, C1-C6 alkyl or amino acid; R2 is H or unsaturated or saturated (C1-C30) alkyl chain; R3 is unsaturated or saturated (C1-C30) alkyl chain; Q1 is a primary amine group (—NH2), secondary amine group (—NH—) or an amide group (—NH—CO—); and t is 0 or 1, or a precursor, a derivative or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention and/or treatment of a disorder selected from the group consisting of insulin resistance, diabetes type 2 and Metabolic Syndrome.
Type:
Application
Filed:
February 11, 2009
Publication date:
August 13, 2009
Applicant:
NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO
Inventors:
Willem Ferdinand Nieuwenhuizen, Aloysius Maria Havekes, Josephus Jan Emeis
Abstract: The present invention relates to the induction of hypothermia in humans in a predictable and dose responsive fashion by use of a pharmaceutical composition comprising a vanilloid receptor agonists, capsaicinoid or capsaicinoid-like agonist capable of inducing hypothermia, thereby benefiting patients suffering from illnesses characterized by tissue anoxia.
Abstract: A cosmetic or dermatological preparation for combating or substantially preventing pollen allergies. The preparation comprises panthenol, glycerol and at least one of citrate and bisabolol and has at least one of (i) a pH of from about 4.6 to about 5.4, (ii) a mass ratio of panthenol to citrate of from about 25:1 to about 5:1, based on citrate anion, and (iii) a mass ratio of panthenol to bisabolol of from about 5:1 to about 1:1. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.
Type:
Application
Filed:
January 27, 2009
Publication date:
July 30, 2009
Applicant:
BEIERSDORF AG
Inventors:
Rainer KROEPKE, Kerstin BOHNSACK, Frank RIPPKE, Alexander FILBRY
Abstract: The present invention relates to the use of compounds as broad spectrum inhibitors of bacterial biofilm formation. In particular the invention refers to a family of compounds that block the quorum sensing system of Gram-negative and Gram-positive bacteria, a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of bacterial damages and diseases, in particular for diseases where there is an advantage in inhibiting quorum sensing regulated phenotypes of pathogens.
Type:
Application
Filed:
December 17, 2008
Publication date:
July 30, 2009
Inventors:
Aldo Ammendola, Tanja Wieber, Andreas Wuzik, Martin Lang
Abstract: The invention relates to the use of compounds for the preparation of a medicament for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. The invention additionally relates to a pharmaceutical composition comprising compounds for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. A method for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration is also provided.
Type:
Application
Filed:
March 20, 2009
Publication date:
July 16, 2009
Applicant:
Yissum Research Development Company of The Hebrew University of Jerusalem
Inventors:
Meir BIALER, Boris YAGEN, IIan WINKLER, Marshall DEVOR
Abstract: The present invention relates to insecticidal compositions comprising compounds having an inhibitory activity versus acyl CoA: cholesterol acyltransferase (ACAT) or salts thereof as effective ingredients. The compounds having inhibitory activity versus ACAT have an excellent insecticidal effect by inhibiting sterol metabolism in noxious insects. Therefore, the compounds of the present invention can be used as safe and effective insecticides.
Type:
Application
Filed:
January 21, 2009
Publication date:
July 16, 2009
Inventors:
YOUNG-KOOK KIM, Hyun-Sun Lee, Mun-Chual Rho, Sung-Uk Kim
Abstract: Compounds which can be represented by the general formula (I) indicated below: and in which: A is selected independently from the carboxamide group, the thiocarboxamide group, and the carbonyl group, R1 is selected from an alkyl group having from 1 to 3 carbon atoms and the amino group, unsubstituted or substituted with the nitro group or the methyl group, R2 is selected independently from hydrogen, an alkyl group having from 1 to 4 carbon atoms, the methoxy, ethoxy, propoxy group, a mono-, bi- or tricyclic cycloalkane residue having from 5 to 12 carbon atoms, the adamantyl group, an aryl, naphthyl or heterocyclic group, unsubstituted or substituted with methyl, methoxy, hydroxy, amino or halogen groups, R3 and R4 are selected independently from hydrogen and an alkyl group having from 1 to 3 carbon atoms, R5 represents one or two substituents independently selected from hydrogen and the methyl, methoxyl and hydroxyl groups, n is a whole number from 0 to 6, and the amidine group is in the para or meta p
Type:
Grant
Filed:
April 30, 2008
Date of Patent:
July 14, 2009
Assignee:
Rotta Research Laboratorium S.p.A.
Inventors:
Francesco Makovec, Simona Zanzola, Roberto Artusi, Lucio Claudio Rovati
Abstract: The invention provides a novel ?2 adrenergic receptor agonist in crystalline salt form. The invention also provides pharmaceutical compositions comprising the novel ?2 adrenergic receptor agonist in crystalline salt form, formulations containing the pharmaceutical compositions, methods of using the crystalline salt to treat diseases associated with ?2 adrenergic receptor activity, and processes useful for preparing such crystalline compounds.
Abstract: The present invention relates to compositions containing signal transduction modulator compounds, to methods for treating or preventing inflammation, or promoting healthy joints, using the compounds and to kits for the same.
Type:
Application
Filed:
June 13, 2006
Publication date:
June 18, 2009
Applicant:
SIGNUM BIOSCENCES, INC.
Inventors:
Jeffry B. Stock, Joel Gordon, Maxwell Stock, Gregory Stock
Abstract: The invention concerns a material, preferably adhesive, for releasing an active molecule for cosmetic use or personal care or a pharmaceutically or biologically active molecule for pharmaceutical use, which is formed of a silicone substance, preferably adhesive, wherein is incorporated said molecule and a compatibility agent wherein said active molecule is soluble, said compatibility agent being selected among isopropyl myristate, isopropyl palmitate, isononyl isononanoate, neopentyl glycol dioctanoate, branched paraffins, organofunctional silicones, or a silicone oil consisting of a cyclic concatenation of 4, 5, 6 or 7 D-siloxyl units of formula: (R)2SiO2/2 formula wherein the symbols R, identical or different, represent each a linear or branched C1-C6 alkyl radical, preferably methyl or an alkyl or arylalkyl radical having 6 to 8 carbon atoms, preferably phenyl. The invention also concerns an object incorporating or consisting of such a material.
Abstract: A method of treating a poison-caused pathology in an individual subject is described which includes administering a pharmaceutical composition including a therapeutically effective amount of a chloride current modulator, a therapeutically effective amount of an exogenous oxygen carrier, or a combination of a therapeutically effective amount of a chloride current modulator and a therapeutically effective amount of an exogenous oxygen carrier, to an individual subject exposed to a poison. Optionally, an inventive method further includes administering a therapeutic agent to inhibit poison-caused pathology. A composition according to the invention is described which includes a therapeutically effective amount of a chloride current modulator, a therapeutically effective amount of an exogenous oxygen carrier, or a combination of a therapeutically effective amount of a chloride current modulator and a therapeutically effective amount of an exogenous oxygen carrier.
Type:
Application
Filed:
November 29, 2005
Publication date:
May 7, 2009
Inventors:
Csaba K. Zoltani, Gennady E. Platoff, Steven I. Baskin
Abstract: A novel method for the preparation of a highly densified and at least partly, preferably fully or almost fully hydrated ceramic for use in the preparation of a pharmaceutical composition notably for controlled-release of one or more therapeutically, prophylactically and/or diagnostically active substance. The method involves a concomitant step of hydrating and densifying a bioresorbable and hydratable ceramic such as calcium sulphate. The invention also relates to compositions comprising such a highly densified ceramic. The pharmaceutical composition is useful for targeted and controlled local prolonged release of active substances, e.g. anti-cancer agents, whereby the spectrum and severity of side effects are minimized due to an optimized local concentration-time profile.
Abstract: Methods of preparing compounds of formula (I): wherein Y, Y1, and R2 are defined herein; methods of making D-(threo)-1-aryl-2-acylamido-1-propanol compounds, D-(threo)-1-aryl-2-acylamido-3-fluoro-1-propanol compounds, and D-(threo)-1-aryl-2-acylamido-3-hydroxy-1-propanol compounds (collectively, “fenicol compounds”) from the compound of formula (I); and new fenicol compounds, which can be made using the method.
Type:
Grant
Filed:
January 31, 2007
Date of Patent:
April 14, 2009
Assignee:
Idexx Laboratories
Inventors:
Yerramilli V. S. N. Murthy, Felix Vattakunnel
Abstract: A method and apparatus for administering drugs through a dermal or mucosal layer such that the treatment device may be applied to the mammal for the transdermal or transmucosal administration of various drugs, pharmaceuticals, salts and prodrugs thereof is taught herein. The magnetic device has at least one magnet to provide an effective magnetic sphere of influence of the magnetic field at the desired site of action. The tissue-permeable drug formulation is positioned on the site of action and the magnetic device is positioned adjacent to tissue-permeable drug formulation wherein the magnetic sphere of influence of the magnetic field moves the drug through the dermal or mucosal layer by interaction with the magnetic moment (induced or permanent) of the drug sufficient to increase the movement of the drug beyond the movement caused by diffusion alone.
Type:
Application
Filed:
October 3, 2008
Publication date:
April 9, 2009
Inventors:
WILLIAM A. FARONE, W. BRADLEY WORTHINGTON
Abstract: Masked nitrogen-substituted and oxygen-substituted neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.
Type:
Application
Filed:
September 5, 2008
Publication date:
March 26, 2009
Inventors:
Bernd Jandeleit, Yunxiao Li, Mark A. Gallop, Noa Zerangue, Peter A. Virsik, Wolf-Nicolas Fischer
Abstract: Masked carboxylate neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.
Type:
Application
Filed:
September 5, 2008
Publication date:
March 12, 2009
Inventors:
Bernd Jandeleit, Yunxiao Li, Mark A. Gallop, Noa Zerangue, Peter A. Virsik, Wolf-Nicolas Fischer
Abstract: The invention relates to a sulfur-containing compound and the preparation thereof. The invention also relates to the uses of the sulfur-containing compound in inhibiting inducible nitric oxide synthase and/or cyclooxygenase-2 and in treating the diseases associated with inducible nitric oxide synthase and/or cyclooxygenase-2. This invention also describes a series of chemical analogues of the said sulfur-containing compound and the preparation of these compounds.
Abstract: The present invention provides a sore throat relief composition and a method of producing the composition comprising oleoresin capsicum containing capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, and homocapsaicin as active ingredients, combined with vegetable glycerin, purified water, spearmint oil, wild cherry bark, clove honey, and ascorbic acid for fully relieving and preventing chronic and occasional sore throat symptoms, including pain, dryness, and inflammation.
Abstract: Compounds, pharmaceuticals, cosmetic or dietary supplements for the treatment of overweight, obesity and/or type II diabetes in a mammal (e.g. human) comprising a compound with formula I or formula II for example ceramidase-inhibitor, such as (1S,2R)-D-ery-thro-2-(N-myristoylamino)-1-phenyl-1-propanol, alone or in combination with an anorexic lipid (or other appetite-inhibiting acylamides or oleoyl-estrone), and methods of treatment comprising administration of said compounds, pharmaceuticals, cosmetic or a dietary supplements. The compounds, pharmaceuticals, cosmetic or dietary supplements and methods of the invention may further be used in modifying the feeding behaviour, suppression of hunger, enhancement of satiety, reduction of energy intake, reduction of fat tissue mass/lean mass ratio in a mammal (e.g. human).
Type:
Application
Filed:
July 14, 2006
Publication date:
February 26, 2009
Inventors:
Harald S. Hansen, Gitte Petersen, Andreas Artmann, Philip J. Larsen
Abstract: A hydrophile gel system for cosmetic and/or skin care applications. The gel system comprises a detachable carrier film and a hydrogel which contains at least 15 percent by weight of karaya gum and whose water content is less than 5 percent by weight.
Type:
Application
Filed:
January 28, 2006
Publication date:
February 12, 2009
Applicant:
LTS LOHMANN THERAPIE-SYSTEME AG
Inventors:
Frank Theobald, Wolfgang Laux, Rene Eifler
Abstract: Compositions and methods for post-translational modifications that include protein acetylation in the ER lumen and deacetylation in the Golgi apparatus are provided. The disclosed methods are especially suited for the identification of compounds useful for the prevention or treatment of neurodegenerative diseases such as Alzheimer's.
Abstract: The present invention provides, in one aspect, a physiological cooling composition comprising at least one cyclohexane carboxamide, at least one acyclic carboxamide, and at least one stereoisomer of menthyl lactate. In another aspect, disclosed is a method for producing such composition. In still another aspect, disclosed are various consumer products comprising a physiological cooling composition comprising at least one cyclohexane carboxamide, at least one acyclic carboxamide, and at least one stereoisomer of menthyl lactate.
Type:
Grant
Filed:
May 28, 2004
Date of Patent:
January 27, 2009
Assignee:
Millenium Specialty Chemicals, Inc.
Inventors:
Mark B. Erman, Patrick J. Whelan, Joe W. Snow
Abstract: The invention is related to gel preparations capable of absorbing as well as releasing liquid, and the use of such gel preparations in the treatment of wounds.
Type:
Application
Filed:
January 31, 2007
Publication date:
January 22, 2009
Applicant:
EURO-CELTIQUE S.A.
Inventors:
Sabine Scherer, Christian Wagner, Christian Leuner, Wolfgang Fleischer
Abstract: A kit for treating a health condition in a mammal, comprises a ERP57 protein and/or compound for inducing a translocation of an ERP57 protein to a cellular membrane in order to provoke an immunogenic apoptosis. The ERP57 protein may include any one or more of: endogenous ERP57, recombinant ERP57, and ERP57 in mimetic form. The endogenous form of ERP57 may include any one of: a plasma membrane ERP57 and an intracellular ERP57.
Abstract: The present invention relates to the use of an insect repellent, preferably selected from the group 2-(2-hydroxyethyl)-1-methylpropyl 1-piperidinecarboxylate, N,N-diethyl-3-methylbenzamide, dimethyl phthalate, butopyronoxyl, 2,3,4,5-bis(2-butylene)-tetrahydro-2-furaldehyde, N,N-diethylcaprylamide, N,N-diethylbenzamide, o-chloro-N,N-diethylbenzamide, dimethyl carbate, di-n-propyl isocinchomeronate, 2-ethylhexane-1,3-diol, N-octylbicycloheptenedicarboximide or piperonyl butoxide, particularly preferably 2-(2-hydroxyethyl)-1-methylpropyl 1-piperidinecarboxylate, as action enhancer for a second insect repellent, to corresponding compositions, and to the preparation thereof.
Abstract: One aspect of the present invention is directed to a composition. The composition includes a dispersion inducer comprising: H3C—(CH2)n—CHmCHmR, where is a single or double carbon-carbon bond, m is 1 or 2, n is 2 to 15, and R is a carboxylic acid, a salt, an ester, or an amide, where the ester or amide is an isostere or biostere of the carboxylic acid. The composition additionally contains an additive component selected from one or more of the group consisting of biocides, surfactants, antibiotics, antiseptics, detergents, chelating agents, virulence factor inhibitors, gels, polymers, pastes, edible products, and chewable products. The composition is formulated so that when it is contacted with a biofilm produced by a microorganism, where the biofilm comprises a matrix and microorganism on a surface, the dispersion inducer selectively acts on the microorganism and has a suitable biological response without a required direct effect on the matrix to disperse the biofilm.
Type:
Application
Filed:
May 14, 2008
Publication date:
December 25, 2008
Applicant:
Research Foundation of State University of New York
Abstract: There provided a 12-membered-ring macrolactam derivative having antitumor activity: A compound represented by Formula (1) or a salt thereof. In this Formula, R1 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group or a C6-14 arylcarbonyl group; R2 is a hydrogen atom or a C1-6 alkyl group; R3 is a hydrogen atom or a hydroxyl group; R4 is a hydrogen atom or a hydroxyl group; R5 is a hydrogen atom or a C1-6 alkyl group; R6 is a hydrogen atom or a hydroxyl group; and R7 is an acetyl group or the like.
Abstract: The invention relates to methods and products for enhancing and improving recovery of lost memories. In particular the methods are accomplished through the increase of histone acetylation.
Type:
Application
Filed:
November 30, 2007
Publication date:
December 4, 2008
Applicants:
Massachusetts Institute of Technology, President and Fellows of Harvard College, The General Hospital Corporation
Inventors:
Li-Huei Tsai, Andre Fischer, Stephen Haggarty, Weiping Tang
Abstract: Insecticidal compositions characterized by an effective amount of an active ingredient combination comprising (a) one or more compounds selected from the group of acetylcholinesterase inhibitors, sodium channel modulators, chitin biosynthesis inhibitors, juvenile hormone mimetics, chloride channel activators, ecdysone agonists, GABA-controlled chloride channel antagonists or acaricides, and (b) at least one crop plant tolerance promoter compound from the group of compounds specified in the description, which are used for controlling arthropods, and also methods of controlling arthropods through the treatment of plants and their seed with these compositions.
Abstract: The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent.
Type:
Application
Filed:
December 10, 2004
Publication date:
November 20, 2008
Applicant:
NitroMed, Inc.
Inventors:
David S. Garvey, Xinqin Fang, Subhash P. Khanapure, Ramani R. Ranatunga, Shiow-Jyi Wey
Abstract: A method for treating prostate related diseases in a subject, the method comprising i) optionally administering to subject an initial boost dose of one or more active substances and/or prodrugs, and ii) administering locally into the prostate a controlled release pharmaceutical composition comprising one or more active substances in a biodegradable ceramic carrier. The biodegradable hydrating ceramic may be selected from the group consisting of non-hydrated or hydrated calcium sulphate, calcium phosphate, calcium carbonate, calcium fluoride, calcium silicate, magnesium sulphate, magnesium phosphate, magnesium carbonate, magnesium fluoride, magnesium silicate, barium sulphate, barium phosphate, barium carbonate, barium fluoride, barium silicate, or mixtures thereof. In a specific embodiment, the biodegradable hydrating ceramic is non-hydrated or hydrated calcium sulphate.
Type:
Application
Filed:
March 31, 2006
Publication date:
November 20, 2008
Applicant:
Lidds Ab
Inventors:
Hans Lennernas, Bo Lennernas, Jonas Hugosson, Niklas Axen
Abstract: The present invention relates to oil-based formulations of hydrophobic drugs for the uniform coating of medical devices such as vascular stents and balloons. Another aspect of the present invention is an intravascular medical device having an oil-based coating suitable for delivering a water-insoluble drug, comprising one or more of an anti-oxidant, an anti-inflammatory and an anti-restenotic agent.
Abstract: A process is described for strengthening the barrier function of undamaged skin in particular against allergens and/or for preventing or inhibiting an allergic reaction of undamaged skin on contact with an allergenic active ingredient, with the following step: Preparation of a mixture comprising: (c) a ceramide and/or a pseudoceramide and (d) an anti-irritant Application of an effective amount of the mixture to the undamaged skin.
Abstract: The present invention is directed to a method of inhibiting CDld activation by administering a composition containing a moiety that blocks CDld activation. Compositions of the invention are useful for the attenuation of CDld-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration.
Type:
Application
Filed:
June 25, 2008
Publication date:
October 23, 2008
Applicant:
Dana-Farber Cancer Institute, Inc.
Inventors:
S. Brian Wilson, Glenn Dranoff, Silke Gillessen